Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 19, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals Inc., USA, the American subsidiary of Glenmark Pharmaceuticals, is set to launch Micafungin for Injection USP in two strengths — 50 mg/vial and 100 mg/vial (single-dose vials) — in the US market starting September 2025. The product is bioequivalent and therapeutically equivalent to Astellas Pharma's Mycamine® for Injection (NDA – 021506). According to IQVIA data for the 12 months ending June 2025, the reference drug's US market achieved annual sales of roughly $60.7 million. The launch is part of Glenmark's strategy to grow its institutional channel portfolio and offer affordable alternatives to patients in the US.
This expands Glenmark's US product portfolio in the institutional/hospital channel and opens up access to a ~$60.7 million annual market. While positive for long-term US revenue diversification, the financial contribution at launch is likely modest relative to Glenmark's overall scale and unlikely to move the stock sharply on its own.